Form 4: Director Lori Kunkel Sells Enliven Therapeutics Stock

Director Lori Kunkel reported a sale of Enliven Therapeutics, Inc. common stock totaling 10,000 shares, executed under a Rule 10b5-1 trading plan.

Summary

• Lori Kunkel, a Director at Enliven Therapeutics, Inc., reported the sale of 10,000 shares of common stock on July 6, 2026.
• The sales were conducted under a pre-established Rule 10b5-1 trading plan adopted on March 6, 2026.
• The first transaction involved 4,111 shares sold at a weighted average price of $49.9834, with individual sale prices ranging from $49.40 to $50.395.
• The second transaction involved 5,889 shares sold at a weighted average price of $50.8442, with individual sale prices ranging from $50.4306 to $51.3752.
• Following these transactions, Kunkel beneficially owns 47,773 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the director's sale of stock, although the execution under a 10b5-1 plan mitigates concerns about opportunistic selling.

Negatives

• Director Lori Kunkel sold a significant number of shares (10,000) in the company.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly when executed under a 10b5-1 plan, are common and often reflect personal financial planning rather than a negative view of the company's prospects. However, significant sales by directors can sometimes be interpreted by the market as a lack of confidence.

Stakeholder Impact

• Shareholders may view the director's sale of stock negatively, potentially leading to short-term price pressure, although the 10b5-1 plan provides context for the transaction.

Key Dates

Recommendation

The filing reports a routine stock sale by a director under a pre-arranged trading plan, which is not indicative of a fundamental change in the company's outlook. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or financial performance updates.

Keywords

Enliven Therapeutics, Lori Kunkel, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director Sale, Common Stock